Abstract:Abstract Background Osteosarcoma (OS) is the most common malignant tumor of bone, and the clinical efficacy of current treatments and associated survival rates need to be further improved by employing novel therapeutic strategies. Although various studies have shown that BMI1 protein is universally upregulated in OS cells and tissues, its specific role and underlying mechanism have not yet been fully explored. Methods Expression of BMI1 protein in OS cells was detected by western blot. The effect of BMI1 on proliferation and migration of OS cells (143B and U-2OS cell lines) was investigated in vitro using CCK-8, colony formation and transwell assays, and in vivo using subcutaneous tumorigenesis and lung metastasis assays in xenograft nude mice. Expression of epithelial–mesenchymal transition (EMT)-associated proteins was detected by immunofluorescence imaging. Bioinformatic analysis was performed using ENCODE databases to predict downstream targets of BMI1. SIK1 mRNA expression in osteosarcoma cells was detected by quantitative real-time reverse transcription PCR (qPCR). Chromatin immunoprecipitation-qPCR (ChIP-qPCR) was used to investigate expression of BMI1-associated, RING1B-associated, H2AK119ub-associated and H3K4me3-associated DNA at the putative binding region of BMI1 on the SIK1 promoter in OS cells. Results Using both in vitro and in vivo experimental approaches, we found that BMI1 promotes OS cell proliferation and metastasis. The tumor suppressor SIK1 was identified as the direct target gene of BMI1 in OS cells. In vitro experiments demonstrated that SIK1 could inhibit proliferation and migration of OS cells. Inhibition of SIK1 largely rescued the altered phenotypes of BMI1-deficient OS cells. Mechanistically, we demonstrated that BMI1 directly binds to the promoter region of SIK1 in a complex with RING1B to promote monoubiquitination of histone H2A at lysine 119 (H2AK119ub) and inhibit H3K4 trimethylation (H3K4me3), resulting in inhibition of SIK1 transcription. We therefore suggest that BMI1 promotes OS cell proliferation and metastasis by inhibiting SIK1. Conclusions Our results reveal a novel molecular mechanism of OS development promoted by BMI1 and provides a new potential target for OS treatment.

BMI-1, a promising therapeutic target for human cancer.

Bmi-1 Is Related To Proliferation, Survival And Poor Prognosis In Pancreatic Cancer

Polycomb Complex Protein Bmi-1 Promotes Invasion and Metastasis of Pancreatic Cancer Stem Cells by Activating Pi3k/Akt Signaling, an Ex Vivo, in Vitro, and in Vivo Study

The Crucial Roles of Bmi-1 in Cancer: Implications in Pathogenesis, Metastasis, Drug Resistance, and Targeted Therapies

BMI‐1 promotes breast cancer proliferation and metastasis through different mechanisms in different subtypes

BMI-1 in Breast Cancer - Biological Role and Clinical Implications

BMI1 in the heart: Novel functions beyond tumorigenesis

Bmi1 Polycomb Group Protein Acts As A Master Switch For Growth And Death Of Tumor Cells: Regulates Tcf4-Transcriptional Factor-Induced Bcl2 Signaling

Roles of BMI1 in the Initiation, Progression, and Treatment of Hepatocellular Carcinoma

BMI1 Regulates Multiple Myeloma-Associated Macrophage’s Pro-Myeloma Functions

Oncoprotein BMI‐1 Induces the Malignant Transformation of HaCaT Cells

BMI1 Promotes the Progression of Laryngeal Squamous Cell Carcinoma.

BMI1 activates P-glycoorotein via transcription repression of <i>miR</i>-<i>3682</i>-<i>3p</i> and enhances chemoresistance of bladdder cancer cell

Bmi-1 Promotes the Chemoresistance, Invasion and Tumorigenesis of Pancreatic Cancer Cells

Bmi-1, Stem Cells and Cancer

Bmi-1,a Polycomb Group Protein,Plays an Essential Role in Tumorigenesis and Metastasis

BMI-1 activates hepatic stellate cells to promote EMT of colorectal cancer cells

BMI1 promotes osteosarcoma proliferation and metastasis by repressing the transcription of SIK1

Validation of Bmi1 As a Therapeutic Target of Hepatocellular Carcinoma in Mice.

Overexpression of BMI1 confers clonal cells resistance to apoptosis and contributes to adverse prognosis in myelodysplastic syndrome.

BMI1 Promotes Cholangiocarcinoma Progression and Correlates with Antitumor Immunity in an Exosome-Dependent Manner